MX2018005350A - Formulacion de combinacion de dosis fija, eflornitina y sulindaco. - Google Patents
Formulacion de combinacion de dosis fija, eflornitina y sulindaco.Info
- Publication number
- MX2018005350A MX2018005350A MX2018005350A MX2018005350A MX2018005350A MX 2018005350 A MX2018005350 A MX 2018005350A MX 2018005350 A MX2018005350 A MX 2018005350A MX 2018005350 A MX2018005350 A MX 2018005350A MX 2018005350 A MX2018005350 A MX 2018005350A
- Authority
- MX
- Mexico
- Prior art keywords
- eflornithine
- sulindac
- dose combination
- fixed dose
- combination formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940000425 combination drug Drugs 0.000 title abstract 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002759 eflornithine Drugs 0.000 title abstract 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 title abstract 2
- 229960000894 sulindac Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente se proveen formulaciones de combinación de dosis fija de una cantidad farmacéuticamente eficaz de eflornitina junto con una cantidad farmacéuticamente eficaz de sulindaco; también se proveen métodos de uso y métodos de fabricación de estas formulaciones.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562248810P | 2015-10-30 | 2015-10-30 | |
US201662358698P | 2016-07-06 | 2016-07-06 | |
EP16306430 | 2016-10-28 | ||
EP16306429 | 2016-10-28 | ||
PCT/US2016/059689 WO2017075576A1 (en) | 2015-10-30 | 2016-10-31 | Eflornithine and sulindac, fixed dose combination formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018005350A true MX2018005350A (es) | 2018-08-14 |
Family
ID=57256487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005350A MX2018005350A (es) | 2015-10-30 | 2016-10-31 | Formulacion de combinacion de dosis fija, eflornitina y sulindaco. |
Country Status (14)
Country | Link |
---|---|
US (4) | US10973790B2 (es) |
EP (1) | EP3368029A1 (es) |
JP (2) | JP2018536707A (es) |
KR (1) | KR20180069068A (es) |
CN (1) | CN108366982A (es) |
AU (1) | AU2016343851B2 (es) |
BR (1) | BR112018008651A2 (es) |
CA (1) | CA3003149C (es) |
CL (1) | CL2018001157A1 (es) |
CO (1) | CO2018005491A2 (es) |
HK (1) | HK1258284A1 (es) |
IL (1) | IL259009A (es) |
MA (1) | MA43114A (es) |
MX (1) | MX2018005350A (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973790B2 (en) | 2015-10-30 | 2021-04-13 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
NZ752894A (en) * | 2016-10-06 | 2023-05-26 | Orbus Therapeutics Inc | Formulations for administration of eflornithine |
US10945981B2 (en) | 2019-05-17 | 2021-03-16 | Cancer Prevention Pharmaceuticals, Inc. | Methods for treating familial adenomatous polyposis |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4309442A (en) | 1977-07-11 | 1982-01-05 | Merrell Toraude Et Compagnie | Method for controlling fertility in mammals |
US4330559A (en) | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
US4413141A (en) | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
US4499072A (en) | 1982-11-29 | 1985-02-12 | Merrell Dow Pharmaceuticals Inc. | Process for treating diseases with ODC inhibitors |
US4859452A (en) | 1986-01-17 | 1989-08-22 | Board Of Regents, The University Of Texas System | Methods for the reduction of difluoromethylornithine associated toxicity |
US4925835A (en) | 1986-05-01 | 1990-05-15 | Sloan-Kettering Institute For Cancer Research | Aziridinyl putrescine containing compositions and their uses in treating prostate cancer |
US5002879A (en) | 1986-05-06 | 1991-03-26 | Merrell Dow Pharmaceuticals | Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor |
FR2706255B1 (fr) | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
AU5200098A (en) * | 1996-11-01 | 1998-05-29 | Ilex Oncology, Inc. | Sustained release formulation containing dfmo |
US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
EP1067919A1 (en) | 1998-03-28 | 2001-01-17 | THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA | Dfmo and sulindac combination in cancer chemoprevention |
US7700568B2 (en) | 1998-06-30 | 2010-04-20 | Sloan-Kettering Institute For Cancer Research | Uses of DNA-PK |
JP2002533416A (ja) | 1998-12-23 | 2002-10-08 | ジー.ディー.サール & カンパニー | 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−2インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法 |
US20050037090A1 (en) | 1998-12-23 | 2005-02-17 | Mckearn John P. | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent |
US6753422B2 (en) | 1999-03-01 | 2004-06-22 | O'brien Thomas G. | Odc allelic analysis method for assessing carcinogenic susceptibility |
JP2002544229A (ja) | 1999-05-17 | 2002-12-24 | アイレックス オンコロジー, インコーポレイテッド | 癌の化学的予防および治療のために組み合わせたdfmoおよびセレコキシブ |
US6602910B2 (en) | 2000-03-07 | 2003-08-05 | Ilex Oncology, Inc. | D-enantiomer of DFMO and methods of use therefor |
WO2001068076A2 (en) | 2000-03-07 | 2001-09-20 | Ilex Oncology, Inc. | D-enantiomer of dfmo and methods of use thereof for treating cancer |
JP2004506683A (ja) | 2000-08-24 | 2004-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | α−ジフルオロメチルオルニチン(DFMO)は、ヒト前立腺におけるポリアミンレベルを抑制する |
GB0125492D0 (en) | 2001-10-24 | 2001-12-12 | Astrazeneca Ab | Formulation |
AU2002343609B2 (en) | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
WO2004050025A2 (en) | 2002-11-29 | 2004-06-17 | Forest Laboratories, Inc. | Combination of ibuprofen and oxycodone for acute pain relief |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
NZ565846A (en) * | 2005-07-18 | 2011-12-22 | Horizon Therapeutics Inc | Medicaments containing famotidine and ibuprofen and administration of same |
WO2007075673A1 (en) | 2005-12-20 | 2007-07-05 | University Of Hawaii | Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors |
DK2043637T3 (da) | 2006-07-18 | 2012-05-07 | Horizon Pharma Usa Inc | Fremgangsmåder og medikamenter til administrering af ibuprofen |
NZ583346A (en) | 2007-07-19 | 2012-02-24 | Takeda Pharmaceutical | Solid preparation comprising alogliptin and metformin hydrochloride |
JP5765937B2 (ja) | 2007-08-01 | 2015-08-19 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニSigma−Tau Industrie Farmaceutiche Riunite Societa Per Azioni | 小児腫瘍の治療 |
WO2009022670A1 (ja) * | 2007-08-10 | 2009-02-19 | Takeda Pharmaceutical Company Limited | 速崩壊性錠剤 |
WO2009048932A2 (en) | 2007-10-09 | 2009-04-16 | Children's Medical Center Corporation | Methods to regulate mirna processing by targeting lin-28 |
JP2011516412A (ja) | 2008-03-05 | 2011-05-26 | ビカス セラピューティクス,エルエルシー | 癌および粘膜炎の治療のための組成物および方法 |
US20100120727A1 (en) * | 2008-11-12 | 2010-05-13 | Kyphia Pharmaceuticals, Inc. | Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof |
US20100291165A1 (en) | 2008-12-08 | 2010-11-18 | Glenn Jr Robert Wayne | Personal care composition in the form of an article having a hydrophobic surface-resident coating |
AU2010248803B2 (en) | 2009-05-14 | 2014-05-29 | Arizona Board Of Regents On Behalf Of University Of Arizona | Carcinoma diagnosis and treatments, based on ODC1 genotype |
SG176096A1 (en) | 2009-05-20 | 2011-12-29 | Ranbaxy Lab Ltd | Liquid dosage forms of isotretinoin |
CN101898978A (zh) | 2009-05-31 | 2010-12-01 | 徐锋 | 依氟鸟氨酸前药和偶合物及其使用方法 |
US20110256161A1 (en) | 2010-04-19 | 2011-10-20 | Aminex Therapeutics Inc. | Methods for enhancing immune response |
US9598734B2 (en) | 2010-04-29 | 2017-03-21 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
EP2568978B1 (en) | 2010-05-14 | 2019-04-24 | Arizona Board of Regents on Behalf of University of Arizona | Cancer prevention and treatment based on dietary polyamine content |
US8853423B2 (en) * | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
ES2961381T3 (es) | 2010-06-19 | 2024-03-11 | Memorial Sloan Kettering Cancer Center | Anticuerpos anti-GD2 |
PL2912193T3 (pl) | 2012-10-29 | 2019-03-29 | Arizona Board Of Regents On Behalf Of University Of Arizona | Markery predykcyjne dla terapii przeciwnowotworowej z użyciem inhibitora poliaminy |
GB2513299A (en) | 2013-03-12 | 2014-10-29 | Cellact Pharma Gmbh Biomedizinzentrum | Compounds for targeting cancer stem cells |
JP6574415B2 (ja) * | 2013-10-07 | 2019-09-11 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランド・アンリミテッド・カンパニーBristol−Myers Squibb Holdings Ireland Unlimited Company | アタザナビルおよびコビシスタットのhiv治療製剤 |
KR20150079373A (ko) * | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
WO2015195120A1 (en) | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
WO2016130918A1 (en) | 2015-02-12 | 2016-08-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating neuroblastoma |
US10973790B2 (en) | 2015-10-30 | 2021-04-13 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
-
2016
- 2016-10-31 US US15/771,484 patent/US10973790B2/en active Active
- 2016-10-31 CN CN201680071715.3A patent/CN108366982A/zh active Pending
- 2016-10-31 CA CA3003149A patent/CA3003149C/en active Active
- 2016-10-31 EP EP16794183.0A patent/EP3368029A1/en active Pending
- 2016-10-31 BR BR112018008651A patent/BR112018008651A2/pt not_active IP Right Cessation
- 2016-10-31 MX MX2018005350A patent/MX2018005350A/es unknown
- 2016-10-31 KR KR1020187015233A patent/KR20180069068A/ko not_active Application Discontinuation
- 2016-10-31 JP JP2018543001A patent/JP2018536707A/ja not_active Withdrawn
- 2016-10-31 MA MA043114A patent/MA43114A/fr unknown
- 2016-10-31 AU AU2016343851A patent/AU2016343851B2/en active Active
-
2018
- 2018-04-29 IL IL259009A patent/IL259009A/en unknown
- 2018-04-30 CL CL2018001157A patent/CL2018001157A1/es unknown
- 2018-05-25 CO CONC2018/0005491A patent/CO2018005491A2/es unknown
-
2019
- 2019-01-15 HK HK19100648.5A patent/HK1258284A1/zh unknown
-
2021
- 2021-03-05 US US17/193,588 patent/US11529326B2/en active Active
- 2021-11-17 JP JP2021186911A patent/JP2022028814A/ja active Pending
-
2022
- 2022-11-15 US US18/055,494 patent/US11925613B2/en active Active
-
2024
- 2024-02-07 US US18/435,678 patent/US20240173284A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3003149A1 (en) | 2017-05-04 |
US10973790B2 (en) | 2021-04-13 |
MA43114A (fr) | 2018-09-05 |
US20230172887A1 (en) | 2023-06-08 |
US11925613B2 (en) | 2024-03-12 |
US20240173284A1 (en) | 2024-05-30 |
CN108366982A (zh) | 2018-08-03 |
IL259009A (en) | 2018-07-31 |
JP2018536707A (ja) | 2018-12-13 |
CL2018001157A1 (es) | 2018-09-07 |
US11529326B2 (en) | 2022-12-20 |
US20200009098A1 (en) | 2020-01-09 |
KR20180069068A (ko) | 2018-06-22 |
HK1258284A1 (zh) | 2019-11-08 |
US20210267926A1 (en) | 2021-09-02 |
EP3368029A1 (en) | 2018-09-05 |
CA3003149C (en) | 2023-10-31 |
JP2022028814A (ja) | 2022-02-16 |
AU2016343851A1 (en) | 2018-05-10 |
BR112018008651A2 (pt) | 2018-10-30 |
AU2016343851B2 (en) | 2022-04-07 |
CO2018005491A2 (es) | 2018-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283134A (en) | Formulations of alcohol-resistant drugs | |
CA2956871C (en) | Compounds active towards bromodomains | |
EP3732195A4 (en) | CYTOTOXICITY-INDUCING THERAPEUTIC | |
IL270866A (en) | Fixed-dose compounds | |
EP3324967A4 (en) | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME | |
EP3349796A4 (en) | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES | |
EP3619238A4 (en) | CYTOTOXICITY INDUCING THERAPEUTIC | |
HK1256754B (zh) | 新念珠藻素化合物和綴合物、它們的製備以及它們的治療用途 | |
PH12017501625A1 (en) | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | |
PH12016501841A1 (en) | Immunosuppressant formulation | |
EP3449924A4 (en) | COMPOSITION, ACTIVE SITE OF CROCINES, AND USES THEREOF | |
MX2019010330A (es) | Formulaciones con mejora de la estabilidad. | |
MX2018005350A (es) | Formulacion de combinacion de dosis fija, eflornitina y sulindaco. | |
MX2016004078A (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih). | |
EP3302530A4 (en) | Cdh26 based therapeutic agents and their use | |
EP3687520A4 (en) | FIXED-DOSE COMBINATION FORMULATIONS FOR THE TREATMENT OF PAIN | |
EP3615064A4 (en) | ENRICHED CELL COMPOSITIONS AND THERAPEUTIC USE | |
PL3381457T3 (pl) | Fizjologicznie czynna kompozycja zawierająca n-acetyloglukozaminę do leczenia bólów pleców | |
EP3341481A4 (en) | MICRORNA 328 ANTISENSE COMPOSITION AND THERAPEUTIC USE | |
EP3664800A4 (en) | THERAPEUTIC FORMULATIONS AND USES THEREOF | |
PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis | |
IL291543A (en) | Medical preparations and their use | |
IN2013MU02015A (es) | ||
GB201909280D0 (en) | Solid dose formulation | |
IL259712B (en) | Stable dosage form of conjugated etidronate-cytrabine, and use thereof |